NRC FORM 591M PART 1
(10-2011)
10 CFR 2.201

U.S. NUCLEAR REGULATORY COMMISSION

SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION

1. LICENSEE/LOCATION INSPECTED:	2. NRC/REGIONAL OFFICE
Bothwell Regional Health Center 601 East 14th Street Sedalia, MO 65302-1706 REPORT NUMBER(S) 13-01	Region III U. S. Nuclear Regulatory Commission 2443 Warrenville Road, Suite 210 Lisle, IL 60532-4352

3. DOCKET NUMBER(S)	4. LICENSE NUMBER(S)	5. DATE(S) OF INSPECTION
030-10715	24-16275-01	November 20, 2013

LICENSEE:

The inspection was an examination of the activities conducted under your license as they relate to radiation safety and to compliance with the Nuclear Regulatory Commission (NRC) rules and regulations and the conditions of your license. The inspection consisted of selective examinations of procedures and representative records, interviews with personnel, and observations by the inspector. The inspection findings are as follows:

☑ 1. Based on the inspection findings, no violations were identified.

☐ 2. Previous violation(s) closed.

☐ 3. The violations(s), specifically described to you by the inspector as non-cited violations, are not being cited because they were self-identified, non-repetitive, and corrective action was or is being taken, and the remaining criteria in the NRC Enforcement Policy, to exercise discretion, were satisfied.

_____ Non-cited violation(s) were discussed involving the following requirement(s):

☐ 4. During this inspection, certain of your activities, as described below and/or attached, were in violation of NRC requirements and are being cited in accordance with NRC Enforcement Policy. This form is a NOTICE OF VIOLATION, which may be subject to posting in accordance with 10 CFR 19.11.
(Violations and Corrective Actions)

Statement of Corrective Actions

I hereby state that, within 30 days, the actions described by me to the Inspector will be taken to correct the violations identified. This statement of corrective actions is made in accordance with the requirements of 10 CFR 2.201 (corrective steps already taken, corrective steps which will be taken, date when full compliance will be achieved). I understand that no further written response to NRC will be required, unless specifically requested.

TITLE	PRINTED NAME	SIGNATURE	DATE
LICENSEE'S REPRESENTATIVE			
NRC INSPECTOR	Robert P. Hays		11/20/13
BRANCH CHIEF	Aaron T. McCraw		12/27/13

NRC FORM 591M PART 3
(10-2011)
10 CFR 2.201

U.S. NUCLEAR REGULATORY COMMISSION

Docket File Information

SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION

1. LICENSEE/LOCATION INSPECTED:	2. NRC/REGIONAL OFFICE
Bothwell Regional Health Center 601 East 14th Street Sedalia, MO 65302-1706 REPORT NUMBER(S) 13-01	Region III U. S. Nuclear Regulatory Commission 2443 Warrenville Road, Suite 210 Lisle, IL 60532-4352

3. DOCKET NUMBER(S)	4. LICENSE NUMBER(S)	5. DATE(S) OF INSPECTION
030-10715	24-16275-01	November 20, 2013

6. INSPECTION PROCEDURES USED	7. INSPECTION FOCUS AREAS
87131, 87132	03.01-03.07

SUPPLEMENTAL INSPECTION INFORMATION

1. PROGRAM CODE(S)	2. PRIORITY	3. LICENSEE CONTACT	4. TELEPHONE NUMBER
02120	3	D. H. Roehrs, MD, RSO	(660) 827-9530

☑ Main Office Inspection Next Inspection Date: 11/18/2016

☐ Field Office Inspection

☐ Temporary Job Site Inspection

PROGRAM SCOPE

The licensee was a medical institution authorized for 10 CFR 35.100, 35.200, 35.300, and 35.400 procedures pertaining to permanent seed implants at the location specified on the license. Since the previous inspection, an additional authorized location of use has been added to the license at 3700 W. 10th Street, however, the location was not inspected because the facility is closed on Wednesdays each week.

The licensee's Nuclear Medicine Department routinely conducts a daily average of 10-15 patient studies with a staff of 3 nuclear medicine technologists (NMTs). Iodine-123 is administered for uptake studies and can average none to two patient cases per month. Iodine-131 procedures requiring a written directive averaged 2-3 administrations per month. Thyroid carcinoma therapies averaged 1-2 each year. Palliative therapy administrations averaged 1-2 each year. The licensee receives unit doses from a local nuclear pharmacy as needed. All waste was held for decay-in-storage.

No low dose brachytherapy procedures using I-125 or palladium-103 seeds for prostate implant therapies have been performed since the previous inspection.

Performance Observations

The licensee's available NMTs and medical physicist demonstrated/discussed: (1) survey meter use and calibrations; (2) package check-in procedures; (3) unit dosage prep and safe use; (4) wipe test counting; (5) waste handling; (6) sealed source inventories and leak tests; (7) routine security of licensed material; (8) dose calibrator tests; (9) quarterly radiation safety program audits; (10) any contamination events (one event involving an incontinent I-131 patient); (11) written directives; (12) radiation safety committee meetings; and (13) dosimetry: for 2011: 211mR-DDE, 1770mR-SDE, and 2012: 251mR-DDE and 1840mR-SDE.

The inspector performed independent and confirmatory radiation measurements which indicated results consistent with licensee survey records and postings.